Steven R. Sarkisian

Learn More
PURPOSE To compare the clinical outcomes of the EX-PRESS glaucoma filtration device placed under a partial-thickness scleral flap with trabeculectomy. DESIGN Randomized, prospective, multicenter trial. METHODS A total of 120 eyes in 120 subjects were analyzed, including 59 eyes treated with EX-PRESS and 61 eyes treated with trabeculectomy. Both the(More)
The Ex-PRESS Mini-Glaucoma Device is a glaucoma drainage device used to shunt aqueous from the anterior chamber into a subconjunctival reservoir that is created surgically. It has been used successfully over the last decade with approximately 60,000 implantations worldwide. In an ever-evolving microsurgical environment, the Ex-PRESS glaucoma device is on(More)
INTRODUCTION The study objective was to evaluate the intraocular pressure (IOP) and medication-lowering effect of 2 second-generation trabecular micro-bypass stents in eyes with open-angle glaucoma (OAG) on one preoperative medication. METHODS Fifty-seven qualified phakic eyes with OAG on 1 medication, preoperative medicated IOP of 18-30 mmHg, and(More)
PURPOSE Our purpose was to evaluate the clinical outcomes of the Ex-PRESS miniature glaucoma device placed under a partial-thickness scleral flap as a single procedure or combined with phacoemulsification cataract surgery. METHODS This was a comparative consecutive case series of 345 eyes: 231 eyes treated with Ex-PRESS implant under scleral flap alone(More)
Glaucoma is the second leading cause of blindness in the world. The ultimate cause of vision loss due to glaucoma is thought to be retinal ganglion cell (RGC) apoptosis. Neuroprotection of RGC is becoming an important approach of glaucoma therapy. Several lines of evidence suggest that estrogen has neurotrophic and neuroprotective properties. In this study,(More)
PURPOSE OF REVIEW The use of glaucoma drainage devices (GDD) in the treatment of glaucoma has become widely accepted for cases of refractory glaucoma. Expansion in the indications for implantation of GDD beyond refractory glaucoma is increasingly common. As such, tube implant complications are reviewed to aid in prevention and improve their management. (More)
PURPOSE To determine the efficacy and safety of diode transscleral cyclophotocoagulation (TSCPC) after tube shunt failure. PATIENTS AND METHODS The patient population consisted of 32 eyes of 31 patients with uncontrolled glaucoma. Each eye had a previously implanted aqueous tube shunt and was currently on maximally tolerated medication. Each eye also(More)
UNLABELLED Although glaucoma filtration surgery options are generally effective means of surgically lowering intraocular pressure (IOP), complications have driven innovators to develop novel approaches to the lowering of IOP. Using the suprachoroidal space has been one novel way to avoid these complications. This article reviews how recent innovation has(More)
The Ex-Press Mini Glaucoma Shunt has been available internationally for almost a decade with almost 35,000 implantations world wide. The device shunts aqueous from the anterior chamber to a subconjunctival reservoir in a similar fashion as trabeculectomy, without removal of any sclera or iris tissue. Developments in ophthalmic surgery have been focused on(More)
Ilya Sluch1, MD, Steven Sarkisian2, MD, and Mahmoud Khaimi3, MD Author 1 has no financial interests in the subject matter Authors 2 is a Consultant for Alcon, Ivantis, Aeon Astron, Endooptiks, InnFocus, Sight Sciences, New World Medical, Ellex. Author 2 has research grants from Aeon Astron, Transcend, and Glaukos. Author 2 is also a speaker for Alcon(More)